Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

Čájet eará veršuvnnaid (1)

BACKGROUND<br/> The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa. <br/><br/>METHODS<br/> We performed...

Bibliográfalaš dieđut
Váldodahkkit:	Agnandji, S, Huttner, A, Zinser, M, Bejon, P
Materiálatiipa:	Journal article
Almmustuhtton:	Massachusetts Medical Society 2016

Geahča maid

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
Dahkki: Agnandji, S, et al.
Almmustuhtton: (2016)

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
Dahkki: Anne Rechtien, et al.
Almmustuhtton: (2017-08-01)

Titration methods for rVSV-based vaccine manufacturing
Dahkki: Jean-François Gélinas, et al.
Almmustuhtton: (2020-01-01)

Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
Dahkki: Vianello, E, et al.
Almmustuhtton: (2021)

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
Dahkki: Angela Huttner, et al.
Almmustuhtton: (2018-12-01)

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV
Dahkki: Hiva Azizi, et al.
Almmustuhtton: (2023-05-01)

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.
Dahkki: Selidji T Agnandji, et al.
Almmustuhtton: (2017-10-01)

Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
Dahkki: Eleonora Vianello, PhD, et al.
Almmustuhtton: (2022-02-01)

Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP
Dahkki: Eleonora Vianello, et al.
Almmustuhtton: (2023-12-01)

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
Dahkki: Huttner, A, et al.
Almmustuhtton: (2018)

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola
Dahkki: Jennifer K. Legardy-Williams, et al.
Almmustuhtton: (2020-03-01)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
Dahkki: Joan G. Tell, et al.
Almmustuhtton: (2020-12-01)

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).
Dahkki: Henao-Restrepo, A, et al.
Almmustuhtton: (2016)

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.
Dahkki: Gsell, P, et al.
Almmustuhtton: (2017)

Refined innate plasma signature after rVSVΔG-ZEBOV-GP immunization is shared among adult cohorts in Europe and North America
Dahkki: Paola Andrea Martinez-Murillo, et al.
Almmustuhtton: (2024-01-01)

Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina
Dahkki: Jennifer Tisoncik-Go, et al.
Almmustuhtton: (2023-02-01)

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
Dahkki: Robert W. Cross, et al.
Almmustuhtton: (2020-07-01)

First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine
Dahkki: Fuchs JD, et al.
Almmustuhtton: (2012-09-01)

The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs
Dahkki: Wenguang Cao, et al.
Almmustuhtton: (2023-06-01)

Enhanced production yields of rVSV-SARS-CoV-2 vaccine using Fibra-Cel® macrocarriers
Dahkki: Noam Cohen, et al.
Almmustuhtton: (2024-02-01)

Development of an Integrated Continuous Manufacturing Process for the rVSV-Vectored SARS-CoV-2 Candidate Vaccine
Dahkki: Zeyu Yang, et al.
Almmustuhtton: (2023-04-01)

Recombinant Sudan virus and evaluation of humoral cross-reactivity between Ebola and Sudan virus glycoproteins after infection or rVSV-ΔG-ZEBOV-GP vaccination
Dahkki: Markus H. Kainulainen, et al.
Almmustuhtton: (2023-12-01)

Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
Dahkki: Pejoski, D, et al.
Almmustuhtton: (2020)

Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine
Dahkki: Francesco Santoro, et al.
Almmustuhtton: (2021-01-01)

Being Pregnant during the Kivu Ebola Virus Outbreak in DR Congo: The rVSV-ZEBOV Vaccine and Its Accessibility by Mothers and Infants during Humanitarian Crises and in Conflict Areas
Dahkki: David A. Schwartz
Almmustuhtton: (2020-01-01)

Development of Robust Freeze-Drying Process for Long-Term Stability of rVSV-SARS-CoV-2 Vaccine
Dahkki: MD Faizul Hussain Khan, et al.
Almmustuhtton: (2024-06-01)

Development and scale-up of rVSV-SARS-CoV-2 vaccine process using single use bioreactor
Dahkki: Christopher Ton, et al.
Almmustuhtton: (2023-03-01)

Detectable vesicular stomatitis virus (VSV)–specific humoral and cellular immune responses following VSV–Ebola virus vaccination in humans
Dahkki: Poetsch, J, et al.
Almmustuhtton: (2018)

rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches )
Dahkki: Watson, CH, et al.
Almmustuhtton: (2024)

rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches)
Dahkki: Conall H. Watson, et al.
Almmustuhtton: (2024-11-01)

UV-Inactivated rVSV-M2e-Based Influenza Vaccine Protected against the H1N1 Influenza Challenge
Dahkki: Titus Abiola Olukitibi, et al.
Almmustuhtton: (2024-05-01)

To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity
Dahkki: Amanda N. Pinski, et al.
Almmustuhtton: (2020-09-01)

Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
Dahkki: Teresa E. Sorvillo, et al.
Almmustuhtton: (2021-08-01)

Understanding the Spike Protein in COVID-19 Vaccine in Recombinant Vesicular Stomatitis Virus (rVSV) Using Automated Capillary Western Blots
Dahkki: Paul F. Gillespie, et al.
Almmustuhtton: (2023-01-01)

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
Dahkki: Yfat Yahalom-Ronen, et al.
Almmustuhtton: (2022-02-01)

Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection
Dahkki: Andrea R. Menicucci, et al.
Almmustuhtton: (2017-04-01)

Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
Dahkki: Emmie de Wit, et al.
Almmustuhtton: (2015-04-01)

Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial
Dahkki: Simon Valayer, et al.
Almmustuhtton: (2025-12-01)

Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice
Dahkki: Ian L. McWilliams, et al.
Almmustuhtton: (2019-02-01)

Durability of immune responses induced by three leading candidate ebola vaccine regimes; rVSV ZEBOV, ChAd3 EBO Z-MVA BN-Filo and AdHu26.ZEBOV-MVA BN Filo
Dahkki: Ewer, K, et al.
Almmustuhtton: (2018)